UK markets open in 6 hours 59 minutes

Praxis Precision Medicines, Inc. (PRAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
50.09-0.66 (-1.30%)
At close: 04:00PM EDT
50.09 0.00 (0.00%)
After hours: 04:18PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close50.75
Open50.93
Bid49.60 x 100
Ask50.44 x 100
Day's range49.52 - 50.93
52-week range12.45 - 67.21
Volume124,363
Avg. volume214,518
Market cap856.93M
Beta (5Y monthly)2.88
PE ratio (TTM)N/A
EPS (TTM)-18.69
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est135.00
  • GlobeNewswire

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,800 shares of its common stock and r

  • Zacks

    Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?

    The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • GlobeNewswire

    Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

    Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showca